艾曲泊帕长期治疗儿童慢性免疫性血小板减少症:中国单中心扩展真实世界观察性研究
该单中心回顾性扩展观察研究纳入65例儿童慢性免疫性血小板减少症患者,中位起始艾曲泊帕年龄6.34岁,随访47.07个月。29.23%因稳定应答停药,其中24.62%获得停药后12个月持续应答;18.46%因失去应答换药。起始血小板计数较低和应答时间较长可能与失去应答相关。长期使用未发现新的安全性问题。
要点
- 65例患儿中29.23%(19/65)因稳定应答停用艾曲泊帕,24.62%(16/65)获得停药后12个月持续应答。
- 18.46%(12/65)因失去应答换用其他治疗,中位换药时间19.13个月。
- 失去应答组起始血小板计数较低、应答时间较长,可能为预测因素。
核心结论
- 报告了儿童慢性免疫性血小板减少症患者使用艾曲泊帕超过3年的长期临床数据,长期使用未发现新的安全性问题。
- 起始血小板计数和应答时间可能是艾曲泊帕治疗期间失去应答的预测因素。
研究设计与样本
- 单中心回顾性扩展真实世界观察性研究,纳入先前儿童慢性免疫性血小板减少症研究中的65例患者(28例男性)。
- 艾曲泊帕起始中位年龄6.34岁(范围1.65–14.13岁),随访47.07个月(范围36.00–57.00个月),分析时艾曲泊帕治疗时间40.36个月(范围10.53–56.83个月)。
- 随访时间为2018年9月至2023年6月。
主要发现
- 29.23%(19/65)因稳定应答停用艾曲泊帕,其中24.62%(16/65)获得停药后12个月持续应答,末次记录血小板计数范围56–166×10^9/L(中位107×10^9/L),4.62%(3/65)在停药后5、6、9个月复发。
- 18.46%(12/65)在治疗19.13个月(范围14.53–26.37个月)后因失去应答换用其他治疗:4例换用阿伐曲泊帕,3例换用海曲泊帕,2例换用中药,1例脾切除,2例在艾曲泊帕治疗基础上加用泼尼松龙。
- 34例患者减量并维持持久应答;与减量组相比,失去应答组起始艾曲泊帕时血小板计数较低、应答时间较长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We have previously confirmed the efficacy and safety of eltrombopag (ELT) in children with chronic immune thrombocytopenia (cITP). However, data on both long-term exposure and early use of TPO-RAs are lacking, so further 'field-practice' evidence on treatment is required. Here, we report the long-term follow-up results (between September 2018 and June 2023) of our previous study. The main objective of this study was to retrospectively review our large institutional experience with ITP patients previously enrolled in our paediatric cITP study. We had more than 3 years of follow-up by June 2023 for treatment patterns and outcomes. A total of 65 patients (28 males) were enrolled, with a median age at ELT initiation of 6.34 (range 1.65, 14.13) years and a follow-up of 47.07 (36.00, 57.00) months, with 40.36 (10.53, 56.83) months of ELT therapy at the time of analysis. In total, 29.23% (19/65) of patients discontinued ELT due to stable response, and 18.46% (12/65) of patients switched to other ITP therapies due to loss of response (LOR) after 19.13 (14.53, 26.37) months. Of the 19 patients who discontinued ELT due to a stable response, 24.62% (16/65) achieved a 12 m sustained response off-treatment (SRoT); the last recorded platelet count ranged from 56 to 166 × 109 /L (median 107 × 109/L); and 4.62% (3/65) patients relapsed at 5, 6 and 9 months after discontinuation. Of the 12 patients who LOR to ELT after 19.13 (14.53, 26.37) months of therapy, four switched to avatrombopag, three switched to hetrombopag, two switched to traditional Chinese medicine (TCM), one underwent splenectomy and two received additional prednisolone under ELT treatment. Thirty-four patients who tapered and maintained a durable response. The patients with LOR and the patients with tapering were compared; the platelet count at the start of ELT is lower, and the time to response is longer in the patients with LOR. The platelet count at the start of ELT and the time to response may be the predictive factors for LOR during ELT treatment. We report more than 3 years of long-term clinical data on children with cITP using ELT. These data do not raise any new safety concerns regarding the long-term use of ELT in children with cITP.
引用
- Wang Z, Wang N, Juntao O, et al. Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China. Br J Haematol. 2023. PMID: 38087811. doi:10.1111/bjh.19253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。